Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

NCT03447678 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Pembrolizumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano